Form DEFA14A ALNYLAM PHARMACEUTICALS,
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☑
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☑ Definitive Additional Materials
☐ Soliciting Material Pursuant to §240.14a-12
Alnylam Pharmaceuticals, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☑ No fee required.
☐ Fee paid previously with preliminary materials.
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- EPR Properties Second Quarter 2026 Earnings Conference Call Scheduled for July 30, 2026
- Blue Star Awarded a Contribution up to $250,000 by Nunavut's Discovery, Invest, Grow Program; NI 43-101 Technical Report on the Ulu Gold Project Filed
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share